βk-2C-B

βk-2C-B
Clinical data
Other names	β-Keto-2C-B; bk-2C-B; 4-Bromo-2,5-dimethoxy-β-ketophenethylamine; 2,5-Dimethoxy-4-bromo-β-ketophenethylamine
Routes of; administration	Oral, others
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status	CA: Schedule III; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act; Illegal in Sweden and Switzerland;
Pharmacokinetic data
Onset of action	20–70 minutes
Duration of action	10–40 hours or 10 hours
Identifiers
	IUPAC name 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one;
CAS Number	807631-09-0;
PubChem CID	11288812;
ChemSpider	9463799;
UNII	W6KJ195I24;
CompTox Dashboard (EPA)	DTXSID201045990 ;
Chemical and physical data
Formula	C10H12BrNO3
Molar mass	274.111 g/mol (freebase); 310.572 g/mol (HCl salt) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC(C(=O)CN)=C(OC)C=C1Br;
	InChI InChI=1S/C10H12BrNO3/c1-14-9-4-7(11)10(15-2)3-6(9)8(13)5-12/h3-4H,5,12H2,1-2H3; Key:HFYJGAIOBIDRPX-UHFFFAOYSA-N;

βk-2C-B, or bk-2C-B, also known as 4-bromo-2,5-dimethoxy-β-ketophenethylamine or as β-keto-2C-B, is a psychedelic drug of the phenethylamine and 2C family. It is the β-keto derivative of 2C-B. The drug is taken orally.

The drug acts as a very-low-potency serotonin 5-HT_2A receptor agonist.

βk-2C-B was first described in the scientific literature by Richard Glennon and colleagues in 2004. It was first encountered as a novel designer drug in Europe in 2013. The drug has since become a controlled substance in Canada, Germany, Switzerland, and the United Kingdom.